We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GLP:NYSEGlobal Partners LP Analysis

Data as of 2026-04-06 - not real-time

$45.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Global Partners LP trades around $45, which sits below its DCF‑derived fair value of $51.68, implying a modest upside of roughly 1 % and an undervalued stance relative to the sector’s average PE of 22.8 (GLP PE = 21.3). The stock offers an attractive 6.76 % dividend yield, but the payout ratio of 141 % raises sustainability concerns given thin profit margins (gross = 6 %, net = 0.4 %). Revenue grew 11 % YoY, yet adjusted EBITDA slipped in Q4, reflecting weakness in wholesale and commercial segments despite stronger GDSO margins. Technical indicators are bearish: price is under the 20‑, 50‑ and 200‑day SMAs, MACD is in a bearish configuration and the 30‑day volatility is high at 30.9 %, with support near $40.83 and resistance around $49.03.
Recent material news includes an insider sell by COO Mark Romaine and a modest decline in Q4 adjusted EBITDA, which together add short‑term pressure. However, the partnership’s high‑yield profile, a low beta of 0.73 and a growing earnings outlook (forward EPS = 2.51) support a longer‑run case for value‑oriented investors, provided dividend sustainability can improve.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD and price below key moving averages
  • Recent insider sell signaling potential information asymmetry
  • High short‑term volatility (~31 %)

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Undervalued relative to DCF and sector PE
  • Strong dividend yield offset by high payout ratio
  • Revenue growth of 11 % despite EBITDA dip

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Fundamental undervaluation and modest upside potential
  • Low beta indicating defensive characteristics
  • Potential for dividend policy improvement and margin recovery

Key Metrics & Analysis

Financial Health

Revenue Growth11.00%
Profit Margin0.43%
P/E Ratio21.3
ROE14.08%
ROA3.79%
Debt/Equity307.31
P/B Ratio2.5
Op. Cash Flow$284.8M
Free Cash Flow$177.4M
Industry P/E22.8

Technical Analysis

TrendBearish
RSI45.2
Support$40.83
Resistance$49.03
MA 20$46.17
MA 50$46.97
MA 200$47.45
MACDBearish
VolumeIncreasing
Fear & Greed Index78.8

Valuation

Fair Value$51.68
Target Price$45.50
Upside/Downside1.11%
GradeUndervalued
TypeBlend
Dividend Yield6.76%

Risk Assessment

Beta0.73
Volatility30.90%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.